title: Does surveillance for hepatocellular carcinoma benefit patients with compensated cirrhosis?
authors.affiliation: Department of Surgery, UT Southwestern Medical Center, Dallas, Texas.
authors.forename: Adam
authors.initials: A
authors.lastname: Yopp
authors.affiliation: Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan.
authors.forename: Akbar
authors.initials: A
authors.lastname: Waljee
authors.affiliation: Department of Internal Medicine, UT Southwestern Medical Center, Dallas, Texas.
authors.forename: Amit G
authors.initials: AG
authors.lastname: Singal
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000401:mortality*; D055088:Early Detection of Cancer / Q000379:methods*; D006526:Hepatitis C / Q000150:complications* / Q000188:drug therapy*; D006801:Humans; D008103:Liver Cirrhosis / Q000150:complications*; D008113:Liver Neoplasms / Q000401:mortality*; D008390:Markov Chains
chemical_list: D000998:Antiviral Agents